Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Joerger M, Kloft C.
Mc Laughlin AM, et al. Among authors: fischer s.
Cancer Chemother Pharmacol. 2024 Jun 15. doi: 10.1007/s00280-024-04679-z. Online ahead of print.
Cancer Chemother Pharmacol. 2024.
PMID: 38878207